echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BJC| "dEGFR39 digital PCR panel test" to facilitate liquid biopsy of lung cancer

    BJC| "dEGFR39 digital PCR panel test" to facilitate liquid biopsy of lung cancer

    • Last Update: 2023-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    In the era of precision medicine, accurate diagnosis is the prerequisite
    for precision treatment.
    "dEGFR39" digital PCR panel detection reagent (Epbay Bio) detects 39 mutation sites of EGFR in a single pass, including common mutation sites such as L858R, 19Del and T790M, and rare mutation sites such as L861Q, S768I, G719X, C797S (cis/trans) and 20ins, comprehensive evaluation of performance and verification of liquid biopsy ctDNA clinical samples.
    Its practical effects on efficacy monitoring and other related academic results are listed in the British Journal of Cancer
    "Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay"

    At present, there are three common nucleic acid detection technologies: real-time PCR (qPCR), high-throughput sequencing (NGS) and digital PCR
    。 qPCR is suitable for more conventional clinical molecular detection items, and NGS is suitable for detecting unknown sequences, unknown mutations, and high-throughput multi-locus detection.
    Due to the advantages of high sensitivity, absolute quantification, easy operation, fast results and high cost performance, digital PCR-based dEGFR39 breakthrough simultaneous detection multi-site quantitative detection has significant advantages
    in the clinical quantitative detection application of tumor liquid biopsy.

    Lung cancer is a malignant tumor with the highest incidence and mortality in China, targeted therapy has a significant effect in patients with advanced non-small cell lung cancer (NSCLC) with positive driver gene, and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the routine treatment
    of NSCLC.
    With the deepening of clinical research, the mutational status of EGFR has also developed into multiple monitoring of the whole course of the disease to cope with the changing condition
    Circulating tumor DNA (ctDNA) is an excellent marker for drug-accompanied diagnosis and real-time disease progression, but its low content and high background noise pose high challenges
    for detection methods.
    Digital PCR technology has excellent sensitivity and specificity, and with higher throughput, more complete sites and lower cost detection reagents, it will be able to analyze ctDNA more comprehensively and quickly, and can better serve the clinic in the

    Professor Song Xiang's team from Cangzhou Central Hospital and Professor Chu Li's team from the Provincial Key Laboratory of Liver and Kidney Disease Research in Integrated Traditional Chinese and Western Medicine of Hebei College of Traditional Chinese Medicine cooperated with Aipbay Biotechnology to comprehensively evaluate the performance of the "digital PCR panel detection" technology, and verified its practical effect on ctDNA efficacy monitoring with clinical samples

    Research Methods:

    In this study, retrospective FFPE tissues of 30 patients with NSCLC and paired tissue and plasma samples of 33 patients with NSCLC were collected for analysis

    Based on the "dEGFR39" digital PCR panel detection reagent and the Naica droplet chip digital PCR system, 39 mutation sites of EGFR can be detected in a single pass, including common mutation sites such as L858R, 19Del and T790M, as well as L861Q, S768I, G719X, C797S (cis/ trans) and rare mutation sites such as 20ins

    Research Results:

    The "dEGFR39" detection reagent has extremely high sensitivity
    The study compares the linear relationship between expected mutational abundance (0.
    01%, 0.
    05%, 0.
    1%, 1%, 10%) and measured abundance, and
    R2 is close to 1

    In the plasma of P-15 in patients treated with eclitinib for 368 days, in addition to the original L858R mutation, the emergence of the resistance site T790M has been detected in dEGFR39, 121 days
    earlier than radiographic disease progression.
    Similarly, in patients with P-25 with the 19Del mutation, the emergence
    of drug-resistant mutation sites was observed 43 days in advance of imaging.
    In patients P-23, the abundances of L858R detected by dEGFR39 continued to decline with the treatment of eclitinib, and CT also showed that the patient was effective
    After that, it was found that the abundance of T790M increased, and the patient's condition became stable
    after changing the treatment plan in time.

    Patient P-23


    The "dEGFR39" panel detection method based on Naica digital PCR technology is reliable, sensitive, fast and has multiple sites, which shows obvious advantages
    in predicting drug resistance, treatment monitoring and clinical prognosis after EGFR-TKIs treatment.

    Based on Naica CN digital PCR and other technology platforms, Aipbay Biotechnology (Suzhou) Co.
    , Ltd.
    has continuously developed dozens of genetic testing products for the important genes in tumor precision medicine, providing detection reagents for genetic characteristics at various stages of cancer treatment, making liquid biopsy a confirmatory method for personalized diagnosis and treatment plans, better evaluating the effectiveness of treatment plans, and assisting in the formulation of personalized treatment plans
    。 The company adheres to product quality and focuses on technological innovation, and will provide more high-quality products and comprehensive services
    for clinical practice in the future, including companion diagnosis, efficacy monitoring, prognosis evaluation, cancer screening, etc.
    At the same time, Epbay Biotech provides professional LDT solutions
    based on advanced digital PCR platform and independent patented detection technology.

    Aipbay Biotechnology (Suzhou) Co.
    , Ltd

    Aipbay Biotechnology (Suzhou) Co.
    , Ltd.
    is a national high-tech enterprise and a leading talent enterprise in Suzhou, and has passed ISO13485 and ISO9001 quality system certification
    Obtained a number of national authorized patents and software copyrights related to nucleic acid microdetection and digital PCR detection
    Approved a number of product registration certificates and product filing certificates
    related to multiple PCR technology platforms.
    It has a solid foundation and rich experience in hardware and software such as molecular biology research and experimental technology, and has built a rapid PCR, rapid quantitative PCR, international leading digital PCR detection platform, microscopic imaging acquisition and analysis and other instrument research and development platforms; It has built a micronucleic acid detection and development platform, continued to develop clinical testing products for molecular diagnostic tests such as molecular and cytogenetic testing related to diseases and targeted drug guidance, and has a highly skilled R&D team to undertake a number of provincial and ministerial technology research and development projects

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.